China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
China Resources Boya Bio pharmaceutical Group Co Ltd
Cash from Operating Activities
China Resources Boya Bio pharmaceutical Group Co Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Cash from Operating Activities
¥641.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
79%
|
CAGR 10-Years
22%
|
|
Beigene Ltd
HKEX:6160
|
Cash from Operating Activities
-¥7.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Operating Activities
-¥1.7B
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Operating Activities
¥1.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Operating Activities
¥3.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
106%
|
CAGR 10-Years
47%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Operating Activities
¥1.2B
|
CAGR 3-Years
57%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
641.7m
CNY
Based on the financial report for Dec 31, 2023, China Resources Boya Bio pharmaceutical Group Co Ltd's Cash from Operating Activities amounts to 641.7m CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
22%
Over the last year, the Cash from Operating Activities growth was 8%. The average annual Cash from Operating Activities growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been -4% over the past three years , 79% over the past five years , and 22% over the past ten years .